. Author manuscript; available in PMC: 2017 Jun 5.

Published in final edited form as: Br J Haematol. 2016 Mar 7;173(3):444–455. doi: 10.1111/bjh.13977

Table IV.

Secondary outcomes.

All patients (n = 113)					Subgroup analysis with BM graft (n = 79)
Variable	Cumulative incidence (95% CI)		HR; 95% CI	P-value	Cumulative incidence (95% CI)		HR; 95% CI	P-value
Variable	Conventional GVHD prophylaxis (n = 72)	PTCy (n = 41)	HR; 95% CI	P-value	Conventional GVHD prophylaxis (n = 45)	PTCy (n =34)	HR; 95% CI	P-value
NRM, 2 years,	25% (16–38)	35% (23–54)	1.4; 0.7–2.8	0.3			1.6 (0.6–3.8)	0.3
Progression, 2 years	31% (22–44)	20% (22–37)	0.6; 0.3–1.4	0.2			0.6 (0.3–1.5)	0.3
PFS, 2 years	38% (27–50)	42% (27–57)	0.9; 0.5–1.5	0.7	43% (28–58)	56% (37–72)	0.9 (0.5–1.6)	0.8
OS, 2 years	40% (28–52)	52% (35–67)	0.8; 0.5–1.4	0.5	38% (24–52)	44% (27–60)	0.8 (0.4–1.6)	0.5

BM, bone marrow; CI, Confidence Interval; HR, Hazard Ratio; GVHD, graft-versus-host disease; PTCy, Post-transplant cyclophosphamide; NRM, non-relapse mortality; PFS, progression-free survival; OS, overall survival.